"Maintenance Chemotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatment designed to help prevent a relapse of a disease following the successful primary treatments (INDUCTION CHEMOTHERAPY and CONSOLIDATION CHEMOTHERAPY) with a long-term low-dose drug therapy.
Descriptor ID |
D060046
|
MeSH Number(s) |
E02.319.509
|
Concept/Terms |
Maintenance Chemotherapy- Maintenance Chemotherapy
- Chemotherapies, Maintenance
- Chemotherapy, Maintenance
- Maintenance Chemotherapies
|
Below are MeSH descriptors whose meaning is more general than "Maintenance Chemotherapy".
Below are MeSH descriptors whose meaning is more specific than "Maintenance Chemotherapy".
This graph shows the total number of publications written about "Maintenance Chemotherapy" by people in this website by year, and whether "Maintenance Chemotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2011 | 0 | 2 | 2 |
2012 | 1 | 2 | 3 |
2013 | 0 | 2 | 2 |
2014 | 1 | 3 | 4 |
2015 | 2 | 4 | 6 |
2016 | 1 | 4 | 5 |
2017 | 2 | 6 | 8 |
2018 | 5 | 4 | 9 |
2019 | 2 | 4 | 6 |
2020 | 3 | 9 | 12 |
2021 | 4 | 6 | 10 |
2022 | 1 | 1 | 2 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Maintenance Chemotherapy" by people in Profiles.
-
Significant erythroid megaloblastic changes in patients treated with allopurinol during maintenance chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023 11; 70(11):e30631.
-
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022 12 01; 40(34):3952-3964.
-
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022 07 14; 387(2):132-147.
-
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 02; 164(2):278-287.
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
-
Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers. J Pediatr Hematol Oncol. 2021 Oct 01; 43(7):e987-e990.
-
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2021 12; 31(12):1589-1594.
-
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecol Oncol. 2021 08; 162(2):482-495.
-
Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol. 2021 05; 193(3):e23-e26.
-
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Cancer. 2021 07 15; 127(14):2432-2441.